Chunli Medical (688236) 2024 Third Quarterly Report Review: Performance is under pressure due to joint contract renewals and sports medicine procurement
Chunli Medical (688236): Short-term pressure is optimistic about subsequent recovery
Chunli Medical (688236): Performance is under pressure due to collection execution, R&D investment remains high
Chunli Medical (688236) 2024 Interim Report Review: Sports medicine collection and joint bid renewal have put pressure on performance
Chunli Medical (688236): Inventory processing affects short-term performance and smooth overseas expansion
Chunli Healthcare (688236): Short-term results are under pressure and await subsequent recovery
Chunli Medical (688236): Looking forward to a new stage after collection of domestic artificial joint faucets
Chunli Medical (688236): Better hip coverage is expected, knee replacement is expected
Chunli Healthcare (688236): Performance growth is affected by policies, optimistic about subsequent recovery
Guoxin Securities released a research report on April 10 stating that it gave Chunli Healthcare (688236.SH) a purchase rating. The main reasons for the rating include: 1) the performance was partially affected by collection, and net profit fell 9.7% in 20
Chunli Healthcare (688236): Cash flow improved significantly year on year, overseas revenue increased by 82% year on year
Chunli Medical (688236) Annual Report Review: Short-term performance is affected by collection, and recovery is expected to accelerate in 24 years
Chunli Medical (688236) 2023 Report Review: Collection affects 23-year performance with high overseas business growth
Chunli Medical (688236): The impact of collection is gradually clear, and overseas business expansion is accelerating
Chunli Healthcare (688236): Significant improvement in cash flow, outstanding overseas performance
Chunli Healthcare (688236): Significant improvement in cash flow in 23 years, impressive overseas performance
Chunli Medical (688236): The impact of inventory returns and exchanges is gradually weakening, and international business is expanding rapidly
Chunli Medical (688236): After short-term pressure on performance, the collection era is expected to usher in restorative growth
Chunli Medical (688236): Performance is in line with expectations, joint contract renewal or benefits
Chunli Medical (688236) Company News Research Report: The impact of collection is gradually being cleared, and performance is expected to reach an inflection point
No Data
No Data